GEIS is an internationally renowned non-profit organization focused on the research and development of drugs for sarcoma cancers.

GEIS will be conducting a multi-country, randomized, open-label Phase 2 clinical trial in a first line setting to evaluate camsirubicin head-to-head against doxorubicin in patients with advanced soft tissue sarcoma.

Monopar has recently entered into a collaboration with NorthStar Medical Radioisotopes, LLC, to develop an RIT based on MNPR-101, and our proprietary portfolio of anti-uPAR monoclonal antibodies. NorthStar is an industry-leading producer of medical radionuclides and will leverage their expertise to rapidly identify the optimal radioisotope to couple with MNPR-101.